Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | ACP3 | P15309 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9572670 | 0.90 | HPRT1 (0.47) | NPC1RAB9ASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL11306437 | 0.88 | NPC1 (0.40) | NPC1RAB9ASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL27976524 | 0.86 | PPARG (0.43) | NPC1RAB9ASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1256766 | 0.84 | NPC1 (0.47) | NPC1RAB9ASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL25888 | 0.81 | MTNR1A (0.45) | NPC1RAB9ATDP1CYP1A2CYP2C19 | |
| SCHEMBL11406620 | 0.81 | SRC (0.40) | NPC1RAB9ATDP1MEN1KMT2A | |
| SCHEMBL28561593 | 0.81 | CYP1A2 (0.48) | NPC1RAB9ASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL14803712 | 0.81 | CYP1A2 (0.47) | NPC1RAB9ASLC1A3SLC1A2SLC1A1 | |
| Ethoxycarbonyl Group SCHEMBL27759216 | 0.80 | CYP1A2 (0.44) | NPC1RAB9ATDP1CYP1A2CYP2C19 | |
| SCHEMBL5540320 | 0.79 | MTNR1A (0.43) | NPC1RAB9ATDP1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 887 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020022892-A1 | TUBULYSIN DERIVATIVES AND METHODS FOR PREPARING THE SAME | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2020-01-30 | — | — | WO | claimed |
| CN-102264708-B | Process for producing quinazoline derivative | SHIONOGI & CO | 2015-02-25 | — | — | CN | claimed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | claimed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | claimed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | claimed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | claimed |
| CN-1105712-C | N-cyanoaryl nitrogen heterocyclic compound | BAYER AG (DE) | 2003-04-16 | — | — | CN | claimed |
| US-5965591-A | MONOAMINE OXIDASE INHIBITOR; FOR PROPHYLAXIS AND TREATING PARKINSON'S DISEASE, DEPRESSION AND ALZHEIMER'S DISEASE | SANKYO COMPANY, LIMITED (JP) | 1999-10-12 | — | — | US | claimed |
| EP-0763053-A4 | STEROID DERIVATIVES FOR TREATMENT OF 5 ALPHA REDUCTASE | SMITHKLINE BEECHAM CORP (US) | 1998-09-09 | — | — | EP | claimed |
| EP-0567271-B1 | Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses | SANKYO CO (JP) | 1997-07-02 | — | — | EP | claimed |
| CN-1150801-A | N-cyanoaryl nitrogen heterocyclic compounds | BAYER AG (DE) | 1997-05-28 | — | — | CN | claimed |
| EP-0763053-A1 | STEROID DERIVATIVES FOR TREATMENT OF 5 ALPHA REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1997-03-19 | — | — | EP | claimed |
| US-5536714-A | Steroid derivatives for the treatment of prostatic hypertrophy their preparation and uses | SANKYO COMPANY, LIMITED (JP) | 1996-07-16 | — | — | US | claimed |
| US-5530142-A | REACTING A PHOSPHONATE WITH A VINYL SUBSTITUTED PERHYDROOXAZOLIDIN-4-ONE RING IN PRESENCE OF A CATALYST | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-06-25 | — | — | US | claimed |
| WO-1995033761-A1 | STEROID DERIVATIVES FOR TREATMENT OF 5 ALPHA REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1995-12-14 | — | — | WO | claimed |
| US-5374736-A | L-4-(phosphinylethyl)-1,3-oxazolidin-5-one derivatives as intermediates for synthesis of phosphorus-containing L-amino acids | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-12-20 | — | — | US | claimed |
| EP-0567271-A2 | Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses | SANKYO COMPANY LIMITED (JP) | 1993-10-27 | — | — | EP | claimed |
| US-4443598-A | ANTIBIOTICS AND INTERMEDIATES | SHIONOGI & CO., LTD. (JP) | 1984-04-17 | — | — | US | claimed |
| EP-0011283-A1 | New lactyl tetrapeptide, processes for preparation thereof and pharmaceutical compositions containing it | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-05-28 | — | — | EP | claimed |
| US-4169939-A | PROCESSES FOR THE PRODUCTION OF 3',4'-DIDEOXYKANAMYCIN B | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1979-10-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | NPC1 2404/4885RAB9A 2824/4885SLC1A3 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.